3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Polycythemia Vera
10
Brain Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Leukemia, Myeloid, Chronic-Phase
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Leukemia
9
Glioblastoma
9
Leukemia, Myeloid, Acute
8
Meningioma
7
Head and Neck Neoplasms
7
Gliosarcoma
6
Myelodysplastic Syndromes
4
Glioma
4
Central Nervous System Neoplasms
4
Neoplasms
3
Myeloproliferative Disorders
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
3
Laryngeal Neoplasms
3
Esophageal Neoplasms
3
Treatment-Refractory Solid Tumors
2
Thrombocythemia, Essential
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Pharyngeal Neoplasms
2
Paranasal Sinus Neoplasms
2
Oropharyngeal Neoplasms
2
Myelodysplastic-Myeloproliferative Diseases
2
Hypopharyngeal Neoplasms
2
Congenital Abnormalities
2
Interventions
pembrolizumab
3
enzalutamide
2
blinatumomab
2
abiraterone
2
Stents
2
Neoadjuvant Therapy
2
Immune Checkpoint Inhibitors
2
Cytochrome P-450 Enzyme System
2
soybean oil, phospholipid emulsion
1
durvalumab
1
dostarlimab
1
cemiplimab
1
camrelizumab
1
atezolizumab
1
Surgical Procedures, Operative
1
Surgical Instruments
1
Radiotherapy, Conformal
1
Radiotherapy
1
Passive Cutaneous Anaphylaxis
1
Palliative Care
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Morphine
1
Lidocaine
1
Levobupivacaine
1
Immunotherapy
1
Hydroxyurea
1
Etoposide
1
Etanercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bites and Stings
×
Hydroxyurea
×
Clear all
NCT06063317
2026-03-06
OASIS
Imugene Limited
Phase 1
Terminated
25 enrolled